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Design and synthesis of a biotinylated probe of COX-2 inhibitor nimesulide
analog JCC76
Bo Zhong , Rati Lama , Kerri M. Smith , Yan Xu , Bin Su
Numerous studies have demonstrated overexpression of cyclo
oxygenase 2 (COX 2) in solid malignancies including breast, pros
tate, colon, pancreas, nonsmall cell lung, bladder, and endo
metrium.1–5 Prostaglandin 2 (PGE2), the product of COX 2, pro
motes tumor invasiveness, angiogenesis, and progression in various
cancers.1,4,5 It is therefore reasonable to conclude that inhibition of
COX 2 would arrest carcinogenesis and thus, (1) prevent cancer
development and (2) regress cancer once developed. Corresponding
to these observations and theory, epidemiological, clinical, and pre
clinical studies provide compelling evidence that the use of COX 2
selective inhibitors may reduce the incidence of mammary cancer
and colorectal cancer.6–9 Theoretically, COX 2 inhibitors achieve
all the anti cancer or cancer preventive activity by targeting COX
2. However, these small molecules may also block other cellular
machineries to affect the cancer cell function, which may lead to
cell growth inhibition, apoptosis or necrosis. With the extensive
studies of COX 2 inhibitors about their anti cancer or cancer pre
vention activity, molecular targets of the drugs beyond COX 2
seems play a very important role for their antineoplastic activity.
Many researchers even suggested that COX independent effects
might be fully responsible for the anti cancer properties of some
COX 2 inhibitors.10,11 The phenomenon ismore like an off target ef
fect, which also underscores the needs to explore targets beyond
COX 2, especially in view of emerging toxicity of the COX 2 inhib
itors. Developing nonCOX 2 inhibitory analogs as new anti cancer
drug based on COX 2 inhibitors as lead compound is feasible and
practicable. In fact, this principle has been successfully applied in
the discovery of some new anti cancer drugs. For instance, COX 2
inhibitor Celecoxib weakly inhibits PDK 1 kinase in prostate cancer
cells. It has been used as a molecular scaffold to develop more po
tent PDK 1 inhibitors (no COX 2 inhibitory activity) which block
PI3 K/AKt pathway. The generated new analog, such as OSU
03012 is 20 fold more active than Celecoxib to inhibit tumor cell
proliferation and to induce cell apoptosis, which is currently in a
phase I clinical trial.12,13 Nimesulide (4 nitro 2 phenoxymethane
sulfoanilide) is a nonsteroidal anti inﬂammatory drug with a pref
erential COX 2 inhibitory activity and is available in someAsian and
European countries since 1985. Studies suggest that nimesulide
could induce apoptosis in liver and lung cancer cells; it also
suppressed the development of 2 amino 1 methyl 6 phenylimi
dazo[4,5 b]pyridine (PhIP) induced mammary gland carcinogene
sis in rats.14–17 NonCOX 2 active nimesulide derivatives have
been synthesized. Some analogs were much more active than
nimesulide in suppressing breast cancer cell growth.18 Interest
ingly, the most potent analog JCC76 was selectively potent in
Her2 overexpressed breast cancer cells.19,20 Both in vitro and
in vivo anticancer properties of JCC76 make it a potential new drug
candidate or drug lead for Her2 overexpressed breast cancer.
To rational design more potent analogs of JCC76 based on its
binding pocket and optimize the structure activity relationship
(SAR), it is a prerequisite to identify the speciﬁc molecular target(s)
of JCC76. Although JCC76 exhibited good selectivity to Her2 over
expressed breast cancer cells, it did not show any signiﬁcant block
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21. Compound 5: White powder, 1H NMR (400 MHz, CDCl3) d 7.970 (1H, d,
J = 2 Hz), 7.453 (1H, d, J = 8.4 Hz), 7.232 (1H, s), 7.126 (3H, m), 6.696 (1H, dd,
J = 2, 8.4 Hz), 6.555 (1H, s), 5.047 (2H, s), 2.834 (3H, s), 2.336 (3H, s), 2.313 (3H,
s), 2.242 (1H, tt, J = 3.6, 12 Hz), 1.245–1.985 (10H, m); Compound 6a: White
powder, 1H NMR (400 MHz, CDCl3) d 7.995 (1H, d, J = 2.4 Hz), 7.410 (1H, s),
7.210 (1H, d, J = 8.4 Hz), 7.094 (3H, m), 6.643 (1H, dd, J = 2.4, 8.4 Hz), 5.036 (2H,
s), 3.482 (2H, b), 2.693 (3H, s), 2.317 (6H, s), 2.258 (1H, tt, J = 3.6, 12 Hz), 1.970–
1.174 (18H, m), 0.842 (3H, t, J = 6.8 Hz); Compound 6b: White powder, 1H
NMR (400 MHz, CDCl3) d 7.902 (1H, d, J = 2.4 Hz), 7.509 (1H, s), 7.230 (1H, d,
J = 8.4 Hz), 7.178 (1H, s), 7.091 (2H, m), 6.696 (1H, dd, J = 2.4, 8.8 Hz), 5.001
(2H, s), 3.471 (8H, m), 3.338 (3H, s), 2.792 (3H, s), 2.317 (3H, s), 2.311 (3H, s),
2.253 (1H, tt, J = 3.6, 12 Hz), 1.956–1.254 (10H, m); Compound 8a: White
powder, 1H NMR (400 MHz, CDCl3) d 8.027 (1H, s), 7.883 (1H, s), 7.134 (4H, m),
6.686 (1H, d, J = 8.4 Hz), 5.677 (1H, b), 5.024 (2H, s), 3.487 (2H, b), 3.184 (2H, d,
J = 6.4 Hz), 2.691 (3H, s), 2.312 (7H, m), 2.178–1.290 (26H, m), 0.878 (3H, t,
J = 6.8 Hz); Compound 8b: White powder, 1H NMR (400 MHz, CDCl3) d 8.294
(1H, s), 8.006 (1H, s), 7.854 (5H, m), 7.528 (2H, m), 7.185 (1H, d, J = 8.4 Hz),
7.077 (3H, m), 6.696 (1H, dd, J = 2, 8.4 Hz), 6.589 (1H, s), 4.997 (2H, s), 3.455
(4H, m), 2.680 (3H, s), 2.289 (7H, m), 1.931–1.192 (18H, m); Compound 8c:
White powder, 1H NMR (400 MHz, CDCl3) d 8.201 (1H, s), 8.085 (1H, s), 7.203
(1H, d, J = 8.4 Hz), 7.101 (3H, m), 6.763 (1H, dd, J = 2, 8.4 Hz), 6.186 (1H, s),
6.115 (1H, t, J = 6 Hz), 5.223 (1H, s), 5.040 (2H, s), 4.498 (1H, m), 4.314 (1H, m),
3.488 (2H, m), 3.149 (3H, m), 2.900 (1H, dd, J = 4.8, 128 Hz), 2.717 (1H, d,
J = 124 Hz), 2.684 (3H, s), 2.314 7H, m), 2.195 (2H, t, J = 7.2 Hz), 1.951–1.283
(24H, m); HRMS calculated for C39H58N5O6S2 (M+H)+ 756.3828, found
756.3847.
22. The effect of JCC76 probes on SKBR-3 breast cancer cell viability was assessed by
using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide
assay (MTT) in triplicates. Cells were grown in custommedium in 96-well, ﬂat-
bottomed plates for 24 h, and were exposed to various concentrations of
nimesulide derivatives dissolved in DMSO (ﬁnal concentration 60.1%) in media
for 72 h. Controls received DMSO vehicle at a concentration equal to that in
drug-treated cells. The medium was removed, replaced by 200 ll of 0.5 mg/ml
of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide in fresh
media, and cells were incubated in the CO2 incubator at 37 C for 2 h.
Supernatants were removed from the wells, and the reduced 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide dye was
solubilized in 200 ll/well DMSO. Absorbance at 570 nm was determined on a
plate reader.
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